Press release
Geron to Announce Second Quarter 2023 Financial Results on August 3, 2023
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will
About this update from Geron Corporation
[{"type":"text","content":" FOSTER CITY, Calif.--(BUSINESS WIRE)--\nGeron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its second quarter 2023 financial results on Thursday, August 3, 2023 at 4:00 p.m. Eastern Time via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results, as well as business highlights, at 4:30 p.m. Eastern Time the same day.\n\n\nA live webcast of the conference call and related presentation will be available on the Company’s website at www.geron.com/investors/events. An archive of the webcast will be available on the Company’s website for 30 days.\n\n\nParticipants may access the webcast by registering online using the following link, https://conferencingportals.com/event/SmvlMvWL.\n\n\nAbout Geron\n\n\nGeron is a late-stage clinical biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. Its investigational first-in-class telomerase inhibitor, imetelstat, harnesses Nobel Prize winning science in a treatment that may alter the underlying course of these diseases. To learn more, visit http://www.geron.com/or follow us on LinkedIn.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20230727681262/en/\n\nAron Feingold\nInvestor and Media Relations\[email protected]\[email protected]\n\n\nSource: Geron Corporation","length":4008,"tagName":"div"}]